- Establishing a Limited Population Antibacterial Drug (LPAD) approval mechanism for antibiotics to treat a serious or life-threatening infection for which there is an unmet medical need.
- Providing economic incentives (including tax credits) necessary to facilitate the research and development (R&D) and appropriate use of urgently needed new antibiotics and diagnostics.
- Investing in a strong ID physician workforce to implement key objectives in the National Action Plan for CARB, including leading antibiotic stewardship programs and conducting research and development for new antibiotics, diagnostics and vaccines.
- Providing robust federal funding for each of the agencies with responsibilities for implementing the National Action Plan for CARB.
- Strengthening data collection and surveillance of antibiotic use and antibiotic resistance in human and animal health settings.
- Expanding global coordination of AR activities, including surveillance and R&D.
Sylvia Matthews Burwell, Secretary of Health and Human Services, also recently asked PACCARB
(PDF) to comment on antibiotic, diagnostic and vaccine incentives as well as on prioritizing federal investments in AR. IDSA will continue to promote the work of PACCARB and the administration, as implementation of the National Action Plan continues forward.